Last reviewed · How we verify
NCT06278909
Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study
NA trial testing Trigeminal Nerve Stimulation in Generalized Anxiety Disorder in 10 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Dr. Rafael Freire |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 18 January 2024 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Trigeminal Nerve Stimulation
Conditions studied
- Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
Sponsor
Dr. Rafael Freire
Who can join
Adults 18 to 65, any sex, with Generalized Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD). * The primary objective is to ascertain if TNS is a safe and well-tolerated treatment for patients with TR-GAD. * The secondary objective will be to monitor changes in GAD symptom severity throughout the study. Results from this study will inform a randomized controlled trial to be conducted in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06278909
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trigeminal Nerve Stimulation
Trials testing the same drug.
- NCT04648085 — Effect of Trigeminal Nerve Stimulation on Corneal Nerves and Chronic Ocular Pain · NA · completed
Other recruiting trials for Generalized Anxiety Disorder
Currently open trials in the same condition.
- NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
- NCT07330648 — Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder · Phase 2 · recruiting
- NCT07121712 — Navigated cTBS for the Treatment of Generalized Anxiety Disorder · NA · recruiting
Other Dr. Rafael Freire trials
Trials by the same sponsor.
- NCT04931134 — Treatment of Anxiety Disorders With Trigeminal Nerve Stimulation · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06278909 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Rafael Freire
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06278909.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing